We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

218 hedge funds and large institutions have $1.86B invested in Pacira BioSciences in 2019 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 85 increasing their positions, 54 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 54

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

33% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 30

23% more call options, than puts

Call options by funds: $9.61M | Put options by funds: $7.85M

18% more capital invested

Capital invested by funds: $1.57B → $1.86B (+$287M)

4% more funds holding

Funds holding: 210 → 218 (+8)

3.35% more ownership

Funds ownership: 100.25% → 103.6% (+3.3%)

Holders
218
Holders Change
+8
Holders Change %
+3.81%
% of All Funds
4.74%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.13%
New
40
Increased
85
Reduced
54
Closed
30
Calls
$9.61M
Puts
$7.85M
Net Calls
+$1.77M
Net Calls Change
-$2.46M

Top Buyers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
+$37M
2
PC
Paulson & Co
New York
+$30.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$22.5M
4
PHS
PFM Health Sciences
California
+$19.2M
5
Millennium Management
Millennium Management
New York
+$16.6M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$40.8M
2
CCM
Consonance Capital Management
New York
-$36.2M
3
HM
HealthCor Management
New York
-$26.9M
4
Goldman Sachs
Goldman Sachs
New York
-$12.6M
5
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$6.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
201
New Capital Management
Texas
$9K – – –
FGAM
202
Financial Gravity Asset Management
Texas
$9K +$127 +3 +2%
GI
203
Gradient Investments
Minnesota
$9K +$8.66K +204 New
ASN
204
Advisory Services Network
Georgia
$7K – – –
CFA
205
Carroll Financial Associates
North Carolina
$6K – – –
GWM
206
Geneos Wealth Management
Colorado
$6K – – –
HI
207
Human Investing
Oregon
$6K – – –
VFA
208
Valeo Financial Advisors
Indiana
$6K +$4.25K +100 +323%
CAL
209
Capital Analysts LLC
Pennsylvania
$4K -$4.37K -103 -51%
FRA
210
Front Row Advisors
California
$3K – – –
SF
211
Synovus Financial
Georgia
$3K – – –
PCP
212
Proficio Capital Partners
Massachusetts
$3K +$1.44K +34 +74%
CFGS
213
Concourse Financial Group Securities
Alabama
$2K – – –
CAW
214
Cornerstone Advisors (Washington)
Washington
$2K – – –
BWM
215
BerganKDV Wealth Management
Minnesota
$1K – – –
WT
216
Whittier Trust
California
$1K – – –
AWM
217
AllSquare Wealth Management
New York
$1K +$1.1K +26 New
GT
218
Glenmede Trust
Pennsylvania
$77 – – –
AC
219
Armistice Capital
New York
– -$40.8M -1,072,000 Closed
HM
220
HealthCor Management
New York
– -$26.9M -706,379 Closed
DCM
221
Daruma Capital Management
New York
– -$6.75M -177,242 Closed
BIM
222
Bogle Investment Management
Massachusetts
– -$6.06M -159,166 Closed
Ameriprise
223
Ameriprise
Minnesota
– -$3.5M -92,040 Closed
MOACM
224
Mutual of America Capital Management
New York
– -$3.35M -88,124 Closed
MWNA
225
Marshall Wace North America
New York
– -$3.22M -84,624 Closed
6 7 8
9
10

PCRX Hedge Fund Activity: Q2 2019 in Review

218 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2019, worth a combined $1.86B — up 18% from $1.57B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new PCRX positions and 30 closed out — a net gain of 10 holders — while 85 added to existing stakes and 54 trimmed.

The largest buyer was Nuveen, opening a new position worth an estimated $37M. The largest seller was Armistice Capital, exiting entirely with an estimated $40.8M sold.

  • 218 institutional investors held Pacira BioSciences (PCRX) as of Q2 2019, up from 210 in Q1 2019.
  • Funds reported $1.86B of Pacira BioSciences stock for Q2 2019, up 18% quarter-over-quarter.
  • 40 funds opened new Pacira BioSciences positions in Q2 2019 and 30 closed out, a net change of +10 holders.
  • The largest Pacira BioSciences buyer in Q2 2019 was Nuveen, an estimated $37M added.
  • The largest Pacira BioSciences seller in Q2 2019 was Armistice Capital, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2019.